A Multi-center, Prospective, Observational Study to Describe the siTuation of Blood Lipid mAnagement Among the Population With hypeRtension and/or Type 2 diabeTes in Community Health Center

Lipoprotein Disorder Clinical Trial

Official title:

A Multi-center, Prospective, Observational Study to Describe the siTuation of Blood Lipid mAnagement Among the Population With hypeRtension and/or Type 2 diabeTes in Community Health Center(START-CHC)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05081440
• Other study ID #: START-CHC
• Status: Not yet recruiting
• Start date: December 1, 2021
• Est. completion date: December 1, 2022

Study information

• Verified date: October 2021
• Source: Huashan Hospital
• Contact: yong li
• Phone: +86 13801753494
• Email: liyong606[@]126.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A multi-center, prospective, observational Study to describe the siTuation of blood lipid mAnagement among the population with hypeRtension and/or type 2 diabeTes in Community Health Center

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 5000
• Est. completion date: December 1, 2022
• Est. primary completion date: December 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. The informed consent form (ICF) should be signed before conducting any research-related operations

2. Age =18 years

3. Patients with well-diagnosed hypertension (HTN) and/or type 2 diabetes (T2DM) and have been ill for = 3 months

4. The patient underwent fasting lipid analysis in the past 1 month and the data was fully recorded Exclusion Criteria: 1.Patients with well-diagnosed atherosclerotic cardiovascular disease (ASCVD) 2. Have received any form of lipid-lowering treatment within 4 weeks before the screening period 3. The patient is currently participating in any other clinical trial except this study -

Related Conditions & MeSH terms

• Hypertension
• Lipoprotein Disorder

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Huashan Hospital	Pfizer

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	primary outcome	To evaluate the blood lipid levels and current status of drug treatment in patients with CHC hypertension and/or type 2 diabetes Describe the characteristics of blood lipid treatment in patients with CHC with hypertension and/or type 2 diabetes with LDL-C between 2.6 and 4.1 mmol/L	2022.12.01
Secondary	secondary outcome	To evaluate the ASCVD risk stratification and the level of blood lipids in patients with CHC hypertension and/or type 2 diabetes.; Evaluate the blood lipid level of patients with hypertension and/or type 2 diabetes in CHC with LDL-C between 2.6 and 4.1mmol/L (LDL-C/Non-HDL) To explore the compliance of patients with CHC hypertension and/or type 2 diabetes with LDL-C between 2.6 and 4.1 mmol/L for lipid-lowering therapy.	2022.12.01